Key Financial Figures - Standalone (₹ in lakhs)

Quarterly Performance (Q2 FY27 vs Q2 FY26):

  • Revenue from operations: ₹70,628 (vs ₹57,895 in Q2 FY26)
  • Other income: ₹265 (vs ₹15 in Q2 FY26)
  • Total Income: ₹70,893 (vs ₹57,910 in Q2 FY26)
  • Profit before exceptional items and tax: ₹7,673 (vs ₹5,578 in Q2 FY26)
  • Exceptional items: ₹209 (write-off of Capital Work-in-Progress)
  • Profit before tax: ₹7,673 (vs ₹5,578 in Q2 FY26)
  • Tax expenses: ₹1,905 (vs ₹1,400 in Q2 FY26)
  • Profit for the period: ₹5,768 (vs ₹4,178 in Q2 FY26)
  • Basic EPS: ₹6.32 (vs ₹4.58 in Q2 FY26)

Half-Yearly Performance (H1 FY27 vs H1 FY26):

  • Revenue from operations: ₹1,33,373 (vs ₹1,09,991 in H1 FY26)
  • Profit before tax: ₹14,666 (vs ₹10,103 in H1 FY26)
  • Profit for the period: ₹10,853 (vs ₹9,042 in H1 FY26)
  • Basic EPS: ₹11.89 (vs ₹9.91 in H1 FY26)

Key Financial Figures - Consolidated (₹ in lakhs)

Quarterly Performance (Q2 FY27):

  • Revenue from operations: ₹82,624
  • Total Income: ₹82,879
  • Profit before tax: ₹11,152
  • Profit for the period: ₹9,913
  • Basic EPS: ₹10.86

Half-Yearly Performance (H1 FY27):

  • Revenue from operations: ₹1,52,903
  • Profit before tax: ₹21,090
  • Profit for the period: ₹19,492
  • Basic EPS: ₹21.36

Exceptional Items

The company recorded an exceptional item of ₹209 lakhs (₹2.09 Cr) representing write-off of Capital Work-in-Progress (CWIP) pertaining to the administrative building situated at E1, as part of routine expansion plans.

Balance Sheet Highlights (Standalone as of September 30, 2026)

  • Total Assets: ₹25,540.8 lakhs
  • Non-Current Assets: ₹11,855.6 lakhs
  • Current Assets: ₹13,685.2 lakhs
  • Total Equity: ₹15,130.5 lakhs
  • Non-Current Liabilities: ₹2,400.7 lakhs
  • Current Liabilities: ₹8,009.6 lakhs

Cash Flow Statement (Standalone H1 FY27)

  • Cash from Operating Activities: ₹3,393 lakhs
  • Cash used in Investing Activities: ₹(4,936) lakhs
  • Cash from Financing Activities: ₹1,558 lakhs
  • Net increase in Cash: ₹15 lakhs

Subsidiary Information

The company has 3 subsidiaries: Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, Pinnacle Chile SpA, and 2 step-down subsidiaries: Pharma Go SpA, Tripharma Chile SpA.

Audit Details

The financial results were:

  • Reviewed by the Audit Committee
  • Approved by the Board of Directors on November 3, 2026
  • Audited by Gokhale & Sathe LLP, Chartered Accountants
  • Received unmodified audit opinion

Meeting Details

Board meeting commenced at 2:30 PM and concluded at 4:20 PM on November 3, 2026.

Business Segment

The company has only one business segment i.e. pharmaceuticals.